What Is It?
Three compounds that activate exercise physiology without the treadmill. Each flips a different metabolic switch. Each has a fundamentally different risk profile.
How Does It Work?
Each compound is more potent than the last. MOTS-c is endogenous, gentle — your mitochondria already make it. GW-501516 is synthetic, banned — GSK terminated development after cancer in every animal species. SLU-PP-332 is bleeding edge — WADA banned it before humans tried it. All three turn mice into athletes. None has been proven to do the same in humans.
Compounds Covered
- MOTS-c (endogenous peptide) — AMPK activation, mitochondrial signaling. Gentle. Mouse data only for exogenous use.
- GW-501516 / Cardarine (synthetic) — PPAR-delta agonist. +70% endurance with exercise in mice. Terminated for cancer. Schedule 9 in Australia.
- SLU-PP-332 (synthetic) — ERR pan-agonist. Activates DDIT4 (the exercise gene). First reported 2023. Zero human trials.
Run the Numbers
Compare protocols across exercise mimetics — strength, daily totals, and stack planning. Free, no login required.
Open the Calculator →The Honest Part
- All efficacy data is preclinical (mice).
- GW-501516 has three layers of cancer evidence.
- SLU-PP-332 has zero human trials.
- MOTS-c exogenous use is unstudied in humans.
- WADA bans synthetics but mostly ignores endogenous peptides (inconsistent).
- For research purposes only.
Research Sources
Verified vendors offering this compound for research purposes. Use the vendor-specific code shown on each card for discounts. We may earn commissions from these links.
Track Exercise Mimetics in the App
Peptide Manager Pro tracks 100+ compounds with an interactive knowledge graph, dosing calculator, protocol tracker, and AI research chat. Veteran-owned. $4.99/mo founding rate.
Get the App →